Genetic profiling assays need more studies

March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p50
This article discusses data from a systematic review conducted by researchers at The Johns Hopkins University School of Medicine, which suggested that gene expression technologies for early-stage breast cancer need more evaluation to determine the extent of prediction, which patients would benefit most and how to interpret test results to make treatment decisions. The three types of breast cancer gene expression tests are Oncotype DX, MammaPrint and H/I.


Related Articles

  • Mesenchymal/Stromal Gene Expression Signature Relates to Basal-Like Breast Cancers, Identifies Bone Metastasis and Predicts Resistance to Therapies. Marchini, Cristina; Montani, Maura; Konstantinidou, Georgia; Orrù, Rita; Mannucci, Silvia; Ramadori, Giorgio; Gabrielli, Federico; Baruzzi, Anna; Berton, Giorgio; Merigo, Flavia; Fin, Stefania; Iezzi, Manuela; Bisaro, Brigitte; Sbarbati, Andrea; Zerani, Massimo; Galiø, Mirco; Amici, Augusto // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: Mounting clinical and experimental evidence suggests that the shift of carcinomas towards a mesenchymal phenotype is a common paradigm for both resistance to therapy and tumor recurrence. However, the mesenchymalization of carcinomas has not yet entered clinical practice as a crucial...

  • Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. Abraham, Gad; Kowalczyk, Adam; Loi, Sherene; Haviv, Izhak; Zobel, Justin // BMC Bioinformatics;2010, Vol. 11, p277 

    Background: Different microarray studies have compiled gene lists for predicting outcomes of a range of treatments and diseases. These have produced gene lists that have little overlap, indicating that the results from any one study are unstable. It has been suggested that the underlying...

  • Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Maruani, D M; Spiegel, T N; Harris, E N; Shachter, A S; Unger, H A; Herrero-González, S; Holz, M K // Oncogene;12/6/2012, Vol. 31 Issue 49, p5073 

    The 40S ribosomal S6 kinase 1 (S6K1) is an important regulator of cell growth. Expression of S6K1 is often elevated in breast cancer cells. However, the transcriptional mechanism of S6K1 overexpression is not understood. In this report, we demonstrate that estrogen activates expression of S6K1...

  • Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Litviakov, Nicolay; Cherdyntseva, Nadezhda; Tsyganov, Matvey; Denisov, Evgeny; Garbukov, Evgeny; Merzliakova, Marina; Volkomorov, Victor; Vtorushin, Sergey; Zavyalova, Marina; Slonimskaya, Elena; Perelmuter, Vladimir // Cancer Chemotherapy & Pharmacology;Jan2013, Vol. 71 Issue 1, p153 

    Purpose: We aimed to examine the association between alterations in multidrug resistance (MDR) gene expression, measured before and after neoadjuvant chemotherapy (NAC), and short-term response in a cohort of stage IIA-IIIC breast cancer patients ( n = 84). Methods: All patients were treated...

  • Treatment tailoring based on molecular characterizations. Dinh, P.; Sotiriou, C. // Annals of Oncology;Sep2008 Supplement 7, Vol. 19, p46 

    The article discusses the development of treatment for breast cancer based on molecular characterizations. It states that one of the most significant discoveries from microarray studies has been the reclassification of breast cancer into molecular subtypes. It mentions that gene expression...

  • Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers. Zhou, Xianxiao; Shi, Tongwei; Li, Bailiang; Zhang, Yuannv; Shen, Xiaopei; Li, Hongdong; Hong, Guini; Liu, Chunyang; Guo, Zheng // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: Directly comparing gene expression profiles of estrogen receptor-positive (ER+) and estrogen receptor-negative (ER−) breast cancers cannot determine whether differentially expressed genes between these two subtypes result from dysregulated expression in ER+ cancer or ER−...

  • Targeted gene therapy for breast cancer with truncated Bid. Kazhdan, I.; Long, L.; Montellano, R.; Cavazos, D. A.; Marciniak, R. A. // Cancer Gene Therapy;Feb2006, Vol. 13 Issue 2, p141 

    We studied the efficiency of the proapoptotic factor tBid, targeted to tumor cells using the promoters of the hTERT, Survivin and Muc1 genes, in killing breast cancer cells. tBid is the active fragment of the proapoptotic protein Bid and is generated in response to death receptor activation....

  • Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Lim, Soyoung; Janzer, Andreas; Becker, Astrid; Zimmer, Andreas; Schüle, Roland; Buettner, Reinhard; Kirfel, Jutta // Carcinogenesis;Mar2010, Vol. 31 Issue 3, p512 

    Breast carcinogenesis is a multistep process involving both genetic and epigenetic changes. Since epigenetic changes like histone modifications are potentially reversible processes, much effort has been directed toward understanding this mechanism with the goal of finding novel therapies as well...

  • Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Booy, E P; Henson, E S; Gibson, S B // Oncogene;5/19/2011, Vol. 30 Issue 20, p2367 

    Myeloid cell leukaemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 family that is elevated in a variety of tumour types including breast cancer. In breast tumours, increased Mcl-1 expression correlates with high tumour grade and poor patient survival. We have previously demonstrated that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics